Cristina Damatarca

Senior Vice President, Drug Safety and Pharmacovigilance - Xenon Pharmaceuticals Inc

Dr. Cristina Damatarca has over 20 years’ experience in the biopharmaceutical industry across all stages of development and product commercialization, and has worked in Drug Safety and Pharmacovigilance in multiple leadership capacities, most with global responsibilities.


Cristina received a medical degree from the University of Medicine and Pharmacy in Iasi, Romania, and a PgDip in Pharmacovigilance from the University of Hertfordshire, U.K. Cristina held positions of Vice President and Global Head of Drug Safety and Pharmacovigilance at several pharmaceutical companies of various sizes, she has built multiple safety departments from the ground up, and played key roles in cross functional collaborations for safety evaluation and benefit-risk assessment for new and existing products. Cristina also served in senior roles in the industry including Therapeutic Area Head for the Oncology Signaling Franchise at Genentech-Roche, Global Safety Officer and Chair of the Global Safety Forum at Amgen, and worked in drug safety as Global Safety Officer at other global companies. During her tenure in drug safety and pharmacovigilance at various pharmaceutical companies, Cristina participated in several successful NDA/BLA/MAA filings, Drug Advisory Committees, established the drug safety governance and chaired the company's Drug Safety Committee for multiple organizations, and led the teams who developed REMS - RiskMAP – risk management programs for various products, some of these having played a key role in optimizing the benefit-risk profile of the products. In addition to her work experience in drug safety and pharmacovigilance, Cristina spent several years of her career in Medical Education as Executive Director of Medical Education, Patient Outcomes, and Risks Management at the Neuroscience Education Institute where she provided oversight for the Continuing Medical Education department and led a team of scientists in developing educational programs (CME) in support of Risk Management for various pharmaceutical products. Many of these programs received recognition for innovation and excellence in medical education.


Cristina has published in peer-reviewed journals, including publications in the area of drug safety and pharmacovigilance, and had multiple speaking engagements at various pharmacovigilance and risk management conferences

Cristina Damatarca


  • Tuesday - November 22, 2022 - 16:40

    Cross-Functional Initiatives for Safety, Risk Management, and Pharmacovigilance Activities Across the Product’s Lifecycle

    • Increase transparency and improve awareness in your communication for Safety, Risk Management, and Pharmacovigilance across the product’s lifecycle
    • Bring value to cross functional approaches within safety governance (SMT and SAC), preparing aggregate reports (DSUR/ PBRER), safety surveillance and core data sheet etc.

Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now